[The Innovative Medicine Initiative (IMI)].
The Innovative Medicine Initiative (IMI) is a joint technology initiative jointly implemented by the European Commission and by the European Federation of Pharmaceutical Industries and Associations (EFPIA). The objective of IMI, officially launched on April 30th 2008, is to identify and address the bottlenecks of the drug discovery and development process. IMI will reinforce the public-private partnerships and will be focused towards critical nodes of the drug discovery such as efficacy predictivity, safety predictivity, knowledge management and education and training. This initiative will also reinforce the attractivity of Europe for biomedical science and will then lead to the discovery of novel therapeutic strategies for the patients.
Bril
Antoine
A
Institut de Recherches Servier.
Canet
Emmanuel
E
D016907:Adverse Drug Reaction Reporting Systems; D001709:Biotechnology / Q000458:organization & administration; D002986:Clinical Trials as Topic; D003299:Cooperative Behavior; D015195:Drug Design; D055808:Drug Discovery / Q000458:organization & administration*; D004353:Drug Evaluation, Preclinical; D004345:Drug Industry / Q000458:organization & administration; D064420:Drug-Related Side Effects and Adverse Reactions; D005060:Europe; D006077:Government Agencies / Q000458:organization & administration; D006801:Humans; D017149:Private Sector / Q000458:organization & administration; D012952:Societies / Q000458:organization & administration